Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ozanimod
ozanimod
BMS Flying High in May With Opdivo, Zeposia FDA Approvals
BioSpace
Fri, 05/28/21 - 11:23 am
Bristol Myers Squibb
FDA
clinical trials
Opdivo
Zeposia
ozanimod
ulcerative colitis
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Tue, 06/2/20 - 11:20 pm
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Thu, 03/26/20 - 10:42 am
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Thu, 03/19/20 - 11:06 am
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Sat, 02/22/20 - 11:39 pm
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Sat, 01/11/20 - 12:06 am
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Sun, 11/24/19 - 11:35 pm
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Mon, 08/5/19 - 11:14 am
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Thu, 06/6/19 - 09:53 am
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
Sat, 01/19/19 - 06:35 pm
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Pages
1
2
3
4
next ›
last »